Observational Trial Tolerability and Efficacy of Resiquimod Gel in Patients Treated for Actinic Keratosis.

NCT01806961 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2016-08-03

Study results available
· View outcomes & findings →

Summary

Determine the recurrence rate of actinic keratosis (AK) lesions in patients with complete clinical clearance at the end of the previous trial SP848-AK-1101 at 6 and 12 months of follow-up.

Conditions

  • Actinic Keratosis

Sponsors & Collaborators

  • Spirig Pharma Ltd.

    lead INDUSTRY

Principal Investigators

  • Lars E French, MD · University Clinic of Dermatology, Zurich

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2013-06-30
Completion
2013-09-30

Countries

  • Germany
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01806961 on ClinicalTrials.gov